"Not only is there no bad blood, Biota is quite an admirer of
the integrated and holistic approach that GSK is taking to
influenza," said Cook.
You can find a bigger idiot than Peter Cook.. I think he is trying to describe GSK’ big hole approach to satisfy Relenza demand. As the hole (demand) gets bigger, get a few more men and manually hand shovel to fill the hole and a big machine filling the hole with GSK Pandemic Vaccine.
Peter Cook announced on 28 April:
To assert, right now, that this (swine flu) will cause a massive rise in sales, well, that class of response is erroneous and lacks understanding."
A few days after the idiot’s statement HC readers found GSK’s announcement doubling production before Peter Idiot inform the market on 4 May. Yes, Peter Cook is a great admirer of GSK – he refused their $100m offer, burned another $10m in legal fees and settled for $20m. and then blamed Peter Molloy for launching the law suit. If the relationship with GSK is good, GSK would have told Peter Cook of doubling production – if so why would Peter Cook mislead the market? Is it to drive down prices to maximise his options on 30 June?
We all know Peter Molloy launched the Daiichi’s partnership in 2004 long before Peter Cook put his snout into the Biota trough. Shame on him to mention Peter Molloy launched the law suit and now forget to mention Peter Molloy launched the Daiichi partnership.
Companies Biota has already talked to include …… as well as Roche Holdings AG, maker of Tamiflu.
If Roche takes up LANI, it will be the best news for BTA shareholders.
- Forums
- ASX - By Stock
- BTA
- interview with peter cook
interview with peter cook, page-10
-
- There are more pages in this discussion • 5 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
CC9
Chariot Corporation (ASX:CC9) refines Black Mountain strategy, launching Pilot Mine to seize U.S. lithium opportunity
NEWS
Antler Copper Project hits major permitting milestone – air quality permit advances to final review
LU7
Discover the strong preliminary feasibility of the Bécancour Lithium Refinery, showcasing resilience in a low pricing environment and a strategic plan to capitalize on future price recoveries